S
Somnus Therapeutics
Private drug development company developing an improved therapeutic to address the need of insomnia patients
About Somnus Therapeutics
Somnus Therapeutics, Inc. operated as a specialty pharmaceutical company with a focused, virtual model centered on a single asset. Founded in the summer of 2007 by Gary Cupit in partnership with the life sciences venture capital firm Care Capital, the company was established to address a specific unmet need in the insomnia market. Mr. Cupit, who served as CEO, brought over two decades of pharmaceutical industry experience to the venture, including senior roles at Novartis and as CEO of Sapphire Therapeutics. The company's strategy was to in-license and develop a single drug candidate through mid-stage clinical trials before out-licensing or selling the asset for final development and commercialization.
The company's core business revolved around its sole product, SKP-1041, a novel controlled-release formulation of zaleplon. Somnus secured exclusive worldwide development and commercialization rights for this therapeutic from SkyePharma in June 2007. The product utilized SkyePharma's proprietary Geoclock™ technology, a press-coated tablet designed to delay the release of the active ingredient for a predetermined period. This feature was specifically aimed at patients who suffer from sleep maintenance insomnia, meaning they can fall asleep but awaken in the middle of the night. The delayed-release mechanism was intended to allow patients to fall asleep naturally, with the medication taking effect later to prevent nocturnal awakenings, without causing next-day cognitive impairment.
Somnus Therapeutics' business model was funded through venture capital. After initial seed money from Care Capital, the company raised $15 million in a Series A financing round on February 11, 2010. The round was led by CTI Life Sciences Fund and included Care Capital. This funding was primarily allocated to finance a Phase II clinical trial for SKP-1041. In June 2011, the company announced the successful completion of this Phase 2 dose-ranging study, which met its primary endpoint for improving wake after sleep onset (WASO). Following these positive results, and in line with its initial strategy, Somnus began seeking a buyer or partner to take the drug through Phase III trials and to market. Despite the successful clinical milestone, the company ultimately ceased operations in January 2016.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2007
- Headquarters
- Bedminster Township, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 22.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2010 | $15M | $60M | CTI Life Sciences | — |
Growth signals
Latest recorded traffic for Somnus Therapeutics is 200 monthly website visits, up 11.1% over the last three months. Somnus Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Somnus Therapeutics in the Bedminster Township ecosystem
The Somnus Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
CTI Life Sciences
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Somnus Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Somnus Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









